Nexium Label Updated With Postmarketing Adverse Events
This article was originally published in The Pink Sheet Daily
Newly updated Nexium labeling includes postmarketing reports of adverse events including myalgia and hepatitis. The update comes as AstraZeneca is actively promoting the proton pump inhibitor's use with NSAIDs.
You may also be interested in...
AstraZeneca says the ads will debut "within the coming weeks." The spots will conform to the company's new principles that highlight "direct" presentation of risk/benefit information and the benefits of early detection.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.